Ozempic vs. Wegovy — Same Drug, Different Purpose

If you've spent any time researching GLP-1 weight loss medications, you've almost certainly encountered both "Ozempic" and "Wegovy" — often in confusing or contradictory contexts. Are they the same thing? Is one better than the other? Why does your doctor keep saying you need Wegovy when you've heard Ozempic works for weight loss?

The short answer: Ozempic and Wegovy both contain semaglutide — the exact same active molecule. The differences between them are entirely about FDA approval, dosing, and the regulatory and insurance frameworks that govern their use. Understanding these differences is essential for navigating your options — especially if you're pursuing weight loss through a telehealth provider.

What Is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. GLP-1 is a naturally occurring gut hormone that the body releases in response to eating. It signals the pancreas to secrete insulin, suppresses glucagon (which raises blood sugar), slows gastric emptying to extend satiety, and acts on the brain's appetite and reward centers to reduce hunger and caloric intake.

GLP-1 is rapidly degraded in the body — its natural half-life is only 1–2 minutes. Semaglutide was engineered to resist enzymatic degradation, with a half-life of approximately 7 days, making once-weekly subcutaneous injection practical and effective. The drug was first developed to treat type 2 diabetes, but its profound weight loss effects — observed consistently across clinical trials — led to a dedicated high-dose formulation for obesity treatment.

The Core Difference: FDA Approval

The fundamental difference between Ozempic and Wegovy is their FDA-approved indication:

Feature	Ozempic	Wegovy
Active ingredient	Semaglutide	Semaglutide
Manufacturer	Novo Nordisk	Novo Nordisk
FDA approval	Type 2 diabetes management + cardiovascular risk reduction in adults with T2D and CVD	Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidity
Approval year	2017	2021
Maximum approved dose	2.0 mg/week (0.5 mg and 1.0 mg pens; 2.0 mg pen added in 2022)	2.4 mg/week
Typical maintenance dose for weight loss	1.0 mg/week (off-label)	2.4 mg/week (on-label)
Administration	Once-weekly subcutaneous injection	Once-weekly subcutaneous injection
List price (approximate)	$900–$1,100/month	$1,300–$1,600/month

Why the Dose Difference Matters

Both Ozempic and Wegovy use the same titration principle — starting at a low dose and gradually escalating to minimize GI side effects. But their dose ceilings are different, and this matters clinically.

The landmark STEP 1 trial (published in the New England Journal of Medicine, 2021) tested semaglutide at 2.4 mg weekly specifically for weight management in people without type 2 diabetes. Results showed:

• Mean weight loss of 14.9% of body weight at 68 weeks (vs. 2.4% for placebo)
• Approximately one-third of participants lost 20% or more of their body weight
• Significant improvements in waist circumference, blood pressure, lipids, and physical function

By contrast, the SUSTAIN trials — which used Ozempic doses up to 1.0 mg weekly for type 2 diabetes — showed mean weight loss of approximately 4–6% of body weight, which was a welcome metabolic benefit but not the primary endpoint.

When researchers compared semaglutide 1.0 mg vs. 2.4 mg directly (STEP 5), the 2.4 mg dose produced significantly greater weight loss, confirming a meaningful dose-response relationship for weight reduction. Put simply: the higher Wegovy dose produces substantially better weight loss outcomes than the doses available in standard Ozempic pens.

The 2.0 mg Ozempic Dose

Novo Nordisk added a 2.0 mg Ozempic pen in 2022 for diabetes management, which brings it closer to Wegovy's maintenance dose. However, this pen is approved for type 2 diabetes, not obesity, and carries a different titration schedule designed for glycemic control rather than weight management.

Insurance Coverage: A Critical Practical Distinction

Beyond the clinical differences, the FDA approval divergence creates significant downstream insurance coverage differences — and this is where it gets complicated for patients.

Ozempic Insurance Coverage

Ozempic is approved for type 2 diabetes. If you have a T2D diagnosis, most commercial insurance plans will cover Ozempic (typically with prior authorization). Medicare Part D covers Ozempic under its diabetes indication. Using Ozempic off-label for weight loss without a T2D diagnosis is legally permissible for physicians to prescribe, but insurance will almost certainly deny coverage if the primary diagnosis on the claim is obesity rather than diabetes.

Wegovy Insurance Coverage

Wegovy is approved specifically for obesity/overweight management, which means it should be covered by plans that include obesity medications. The challenge is that many plans — including most Medicare Part D plans until recently — specifically excluded "weight loss" drugs from their formularies. Coverage is expanding, but inconsistently. Employer-sponsored plans that have adopted obesity coverage increasingly include Wegovy, and some states have mandated obesity medication coverage in state-regulated plans.

Practical Advice on Insurance

• If you have type 2 diabetes: Ozempic through your primary care or endocrinologist is likely your most insurance-covered path. Weight loss will be a beneficial side effect.
• If you have obesity or overweight with comorbidities but not T2D: Wegovy is the on-label option. Check your plan's formulary for "semaglutide" or "Wegovy." Novo Nordisk also offers a savings program (Wegovy Savings Offer) for eligible commercially insured patients that can reduce out-of-pocket cost significantly.
• If you are uninsured or underinsured: Compounded semaglutide — when available through a licensed telehealth provider and licensed compounding pharmacy — offers substantially lower costs ($200–$450/month) while providing the same active ingredient.

Is Ozempic "Approved" for Weight Loss?

This is one of the most common points of confusion. Technically, Ozempic is not FDA-approved for weight loss. Wegovy is the FDA-approved semaglutide product for chronic weight management.

However, physicians can legally prescribe Ozempic off-label for weight loss — and many do, particularly for patients who already have a T2D diagnosis or who have insurance that covers Ozempic but not Wegovy. Off-label prescribing is entirely legal and accounts for a substantial portion of all prescribing in the United States.

The important caveat: at the doses available in standard Ozempic pens (up to 1.0 mg weekly for most users), you are less likely to achieve the 15–20% weight loss seen in Wegovy clinical trials. You may still lose meaningful weight, particularly at higher doses, but the dose difference is real and clinically significant.

Compounded Semaglutide: What It Means in This Context

When FDA-listed semaglutide products are on shortage, compounding pharmacies can legally prepare semaglutide under 503A or 503B status. Importantly, compounded semaglutide can be formulated at any dose — meaning telehealth providers can prescribe it at the Wegovy-equivalent 2.4 mg maintenance dose at a fraction of the brand-name cost.

Compounded semaglutide is not the same as Ozempic or Wegovy — it is not FDA-approved as a finished drug product and does not undergo the same quality manufacturing controls. However, when dispensed by a legitimately licensed, PCAB-accredited compounding pharmacy following pharmaceutical-grade standards, it can provide the same therapeutic active ingredient at a substantially lower price point.

Side Effects: Are They Different Between Ozempic and Wegovy?

Because both products contain semaglutide, their side effect profiles are nearly identical. The most common adverse effects are gastrointestinal:

• Nausea: Most common, reported by 40–44% of patients in STEP 1; typically most pronounced during dose escalation and improves over time
• Diarrhea: Reported in approximately 30% of Wegovy patients in trials
• Vomiting: Reported in approximately 24% of patients; dose reduction may help
• Constipation: Reported in approximately 24% of patients; often responds to hydration and dietary fiber
• Abdominal pain: Reported in approximately 20% of patients

At the higher Wegovy dose of 2.4 mg, GI side effects tend to be slightly more pronounced than at the lower Ozempic doses used for diabetes — a tradeoff for the greater weight loss efficacy. This is one reason the slow titration protocol (starting at 0.25 mg and escalating over 16–20 weeks) is so important.

Rare but serious adverse effects to be aware of include pancreatitis, gallbladder disease, and the theoretical (rodent-model-based) concern about medullary thyroid carcinoma — which is why MTC and MEN2 personal or family history are absolute contraindications for both products.

Which Should You Choose?

In practice, the choice between Ozempic and Wegovy is often made for you by your insurance, your diagnosis, and your provider's clinical judgment. But here's a practical framework:

• You have type 2 diabetes + want weight loss: Ozempic is likely your covered option; weight loss is a meaningful benefit. Discuss dose ceiling with your provider.
• You have obesity/overweight + no T2D: Wegovy is the on-label, evidence-based choice for your situation. Check insurance coverage.
• You want maximum weight loss efficacy: The 2.4 mg semaglutide dose (Wegovy or compounded equivalent) has the strongest evidence for significant weight reduction.
• Cost is the primary concern: Compounded semaglutide through a licensed telehealth provider offers the same active ingredient at dramatically lower cost when brand-name options are unaffordable.

The Dose Titration Schedule: What to Expect Week by Week

Both Ozempic (for diabetes) and Wegovy (for weight management) use structured titration protocols to minimize GI side effects. They differ slightly, reflecting their different clinical goals:

Weeks	Ozempic (Diabetes Titration)	Wegovy (Weight Loss Titration)
1–4	0.25 mg/week	0.25 mg/week
5–8	0.5 mg/week	0.5 mg/week
9–12	Maintain 0.5 mg (evaluate for 1.0 mg increase)	1.0 mg/week
13–16	1.0 mg/week (typical maintenance)	1.7 mg/week
17+	1.0–2.0 mg/week based on glycemic response	2.4 mg/week (maintenance)

The Wegovy titration is more extended — 16–20 weeks to reach the full 2.4 mg maintenance dose — because the higher dose ceiling requires careful acclimation. Providers may slow the titration further for patients who experience intolerable GI side effects at any step. Rushing titration in pursuit of faster weight loss is counterproductive and increases discontinuation rates.

For compounded semaglutide, providers typically follow the same general schedule using the Wegovy dosing framework, as the goal is the same: achieving the therapeutic 2.4 mg dose while maintaining tolerability.

Access Through Truventa Medical

Truventa Medical's weight loss programs are designed to navigate exactly these complexities on your behalf. Our licensed providers can evaluate your eligibility for semaglutide — whether brand-name Wegovy, Ozempic (where clinically appropriate), or compounded semaglutide — and help you understand your insurance options and costs before you commit to anything.

Through the OpenLoop physician network, we provide access in all 50 states with no in-person visit required. Our programs include:

• Comprehensive health intake and contraindication screening
• Physician-supervised dosing protocols based on your clinical response
• Side effect management guidance and dosing adjustments
• Regular check-ins to track your progress and refine your plan
• Support navigating insurance prior authorization for Wegovy where applicable
• Access to licensed compounding pharmacy partners for cost-effective options

Whether you're just starting to explore GLP-1 medications or you've been on Ozempic for diabetes and want to transition to an optimized weight loss protocol, Truventa's clinical team is equipped to help you make the right choice for your specific situation.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Results may vary. Consult your doctor before starting any new treatment.